Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 3%

Rapport Therapeutics (NASDAQ:RAPP) shares were up 3% during mid-day trading on Friday . The company traded as high as $21.40 and last traded at $21.11. Approximately 28,859 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 191,473 shares. The stock had previously closed at $20.50.

Analysts Set New Price Targets

RAPP has been the subject of several analyst reports. Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target for the company. TD Cowen assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective for the company.

Rapport Therapeutics Stock Up 7.7 %

Insider Transactions at Rapport Therapeutics

In related news, Director James Healy purchased 44,032 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was acquired at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the acquisition, the director now directly owns 40,851 shares of the company’s stock, valued at approximately $1,001,666.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.